Sponsored By

A Big Three Months for Biotech ETFsA Big Three Months for Biotech ETFs

Biotech-focused ETFs dominated the list of the 20 top-performing funds over the past three months.

Aniket Ullal, CFRA Research, SVP, ETF Research & Analytics

December 5, 2019

21 Slides
Wall Street sign

Already have an account?

JaysonPhotography/iStock/Getty Images Plus

Based on three-month returns. Minimum of $5 million in net assets, excluding leveraged and inverse ETFs.

Data as of 12/2/2019.

 

Aniket Ullal is the founder and CEO of First Bridge Data, a provider of independent ETF data and analytics to institutional clients. Previously he had product management responsibility for S&P’s U.S. indexes, including the widely followed S&P 500 and S&P/Case-Shiller indexes. He is the author of ETF Investment Strategies (McGraw-Hill, 2013).

About the Author

Aniket Ullal, CFRA Research

SVP, ETF Research & Analytics, CFRA Research

http://www.firstbridgedata.com/

Aniket Ullal is SVP, ETF Data and Analytics for CFRA, one of the world’s largest providers of independent investment research. Aniket founded First Bridge Data, a leading source for global ETF data and analytics that was acquired by CFRA in August 2019. 

Prior to starting First Bridge, he had product management responsibility for S&P’s US indices, including the widely followed S&P 500 and S&P/Case-Shiller indices. These indices have over $1Trillion in ETF assets tracking them. 

Aniket is the author of 'ETF Investment Strategies' (McGraw-Hill; 2013). He is a graduate of Northwestern's Kellogg School of Management and the Indian Institute of Management in Ahmedabad.